Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best mid cap growth stocks to invest in now. Earlier on June 5, ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced statistically significant data from the 16-week ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

Nektar Therapeutics said its embattled immune drug rezpeg significantly improved skin clearance rates in patients with atopic ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

ST-100 is a novel collagen mimetic peptide designed to repair damaged collagen in the eye and restore homeostatic cell signaling in the ocular epithelium.

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.